Cargando…

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer: Is Routine Screening Indicated?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Sun, Lova, Aggarwal, Charu, Cohen, Roger B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352329/ https://www.ncbi.nlm.nih.gov/pubmed/34396182 http://dx.doi.org/10.1016/j.jaccao.2019.11.014

Ejemplares similares

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
por: Pirozzi, Flora, et al.
Publicado: (2021)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
por: Raschi, Emanuel, et al.
Publicado: (2023)

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
por: Yousif, Laura I., et al.
Publicado: (2023)

The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond
por: Gilon, Dan, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Imaging assessment of toxicity related to immune checkpoint inhibitors
por: Berz, Antonia M., et al.
Publicado: (2023)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
por: Chitturi, Kalyan R., et al.
Publicado: (2019)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
por: Bukamur, Hazim, et al.
Publicado: (2020)

Indicators of responsiveness to immune checkpoint inhibitors
por: Shields, Bradley D., et al.
Publicado: (2017)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department
por: Niemantsverdriet, Michael S. A., et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
por: Paluri, Ravi Kumar, et al.
Publicado: (2023)

Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
por: Druce, Irena, et al.
Publicado: (2022)

Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist
por: Tattersall, Ian William, et al.
Publicado: (2020)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Imaging features of toxicities associated with immune checkpoint inhibitors
por: Gosangi, Babina, et al.
Publicado: (2022)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies
por: Guo, Xinyu, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II
por: Bukamur, Hazim, et al.
Publicado: (2021)

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
por: Shen, Luhui, et al.
Publicado: (2023)

Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
por: Widmann, Gerlig, et al.
Publicado: (2017)

Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
por: Pezo, Rossanna C., et al.
Publicado: (2019)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021)

Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors
por: Chen, Ru, et al.
Publicado: (2021)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive
por: Gudiol, Carlota, et al.
Publicado: (2022)

Toxicities associated with immune checkpoint inhibitors: a systematic study
por: Kong, Xiangyi, et al.
Publicado: (2023)

Cardiovascular events after the initiation of immune checkpoint inhibitors
por: Suzuki, Yuta, et al.
Publicado: (2023)

Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes
por: Zhou, Ting, et al.
Publicado: (2021)

Hyperacute Onset of Immune Checkpoint Inhibitor–Related Acute Interstitial Nephritis
por: Tawhari, Ibrahim, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mj04184haslmbint84n2304j1e